$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000100069424000007 Filed on February 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$93.86M	$291.3M	$983.7M
YoY Change	15.94%	-18.48%	-50.36%
Cost Of Revenue	$59.21M	$155.0M	$343.8M
YoY Change	73.7%	-14.74%	-61.92%
Gross Profit	$34.65M	$136.4M	$639.9M
YoY Change	-26.07%	-22.36%	-40.7%
Gross Profit Margin	36.91%	46.81%	65.05%
Selling, General & Admin	$86.80M	$155.2M	$457.4M
YoY Change	-22.87%	-3.97%	-6.39%
% of Gross Profit	250.53%	113.84%	71.48%
Research & Development	$92.68M	$164.7M	$737.5M
YoY Change	-62.49%	-36.13%	-40.3%
% of Gross Profit	267.5%	120.78%	115.25%
Depreciation & Amortization	$12.15M	$10.79M	$41.00M
YoY Change	34.32%	49.46%	40.89%
% of Gross Profit	35.06%	7.92%	6.41%
Operating Expenses	$92.68M	$319.9M	$737.5M
YoY Change	-62.49%	-23.74%	-40.3%
Operating Profit	-$144.8M	-$183.6M	-$566.5M
YoY Change	-53.69%	-24.73%	-12.13%
Interest Expense	$4.111M	-$4.117M	$14.42M
YoY Change	-4.75%	-10.52%	-27.48%
% of Operating Profit
Other Income/Expense, Net	$3.654M	$10.98M	$37.90M
YoY Change	-85.0%	-82.83%	245.48%
Pretax Income	-$145.3M	-$176.7M	-$543.0M
YoY Change	-50.37%	-4.23%	-16.92%
Income Tax	$2.262M	$1.688M	$2.031M
% Of Pretax Income
Net Earnings	-$147.6M	-$178.4M	-$545.1M
YoY Change	-49.8%	-2.12%	-17.15%
Net Earnings / Revenue	-157.21%	-61.23%	-55.41%
Basic Earnings Per Share	-$1.05		-$5.41
Diluted Earnings Per Share	-$1.05	-$1.44	-$5.41
COMMON SHARES
Basic Shares Outstanding	140.0M shares	118.8M shares	100.8M shares
Diluted Shares Outstanding	139.9M shares		100.8M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$480.6M	$568.5M	$568.5M
YoY Change	-23.1%	-57.48%	-57.48%
Cash & Equivalents	$480.6M	$568.5M	$568.5M
Short-Term Investments
Other Short-Term Assets	$209.4M	$155.7M	$236.4M
YoY Change	5.19%	103.9%	-4.45%
Inventory	$15.78M	$41.70M	$41.70M
Prepaid Expenses
Receivables	$21.38M	$297.2M	$297.2M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$727.1M	$1.144B	$1.144B
YoY Change	-25.12%	-32.85%	-32.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$291.1M	$305.8M	$491.0M
YoY Change	-5.31%	3.92%	22.6%
Goodwill	$123.2M	$127.5M
YoY Change	-5.12%	0.89%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$30.97M	$35.16M	$35.16M
YoY Change	1.51%	23.5%	23.5%
Total Long-Term Assets	$626.4M	$653.6M	$653.6M
YoY Change	9.58%	17.71%	17.71%
TOTAL ASSETS
Total Short-Term Assets	$727.1M	$1.144B	$1.144B
Total Long-Term Assets	$626.4M	$653.6M	$653.6M
Total Assets	$1.354B	$1.797B	$1.797B
YoY Change	-12.26%	-20.42%	-20.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$57.72M	$132.6M	$132.6M
YoY Change	-53.75%	-38.75%	-38.75%
Accrued Expenses	$257.4M	$394.7M	$417.6M
YoY Change	-50.38%	-33.24%	-31.31%
Deferred Revenue	$240.9M	$241.3M
YoY Change	-42.06%	-39.68%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.291M	$5.142M	$5.142M
YoY Change	422.07%	-98.54%	-98.54%
Total Short-Term Liabilities	$804.4M	$1.635B	$1.635B
YoY Change	-58.08%	-33.53%	-33.53%
LONG-TERM LIABILITIES
Long-Term Debt	$223.0M	$223.9M	$223.9M
YoY Change	12.73%	13.27%	13.27%
Other Long-Term Liabilities	$351.7M	$33.13M	$655.3M
YoY Change	640.3%	-40.52%	178.74%
Total Long-Term Liabilities	$351.7M	$33.13M	$879.3M
YoY Change	640.3%	-40.52%	103.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$804.4M	$1.635B	$1.635B
Total Long-Term Liabilities	$351.7M	$33.13M	$879.3M
Total Liabilities	$2.221B	$2.514B	$2.514B
YoY Change	-8.93%	-13.08%	-13.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.969B	-$4.821B
YoY Change	8.72%	12.75%
Common Stock	$1.417M	$1.405M
YoY Change	62.69%	61.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$867.1M	-$716.9M	-$716.9M
YoY Change
Total Liabilities & Shareholders Equity	$1.354B	$1.797B	$1.797B
YoY Change	-12.26%	-20.42%	-20.42%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$147.6M	-$178.4M	-$545.1M
YoY Change	-49.8%	-2.12%	-17.15%
Depreciation, Depletion And Amortization	$12.15M	$10.79M	$41.00M
YoY Change	34.32%	49.46%	40.89%
Cash From Operating Activities	-$83.60M	-$176.8M	-$714.0M
YoY Change	-74.32%	50.05%	71.68%
INVESTING ACTIVITIES
Capital Expenditures	$6.878M	$8.839M	$53.77M
YoY Change	-65.26%	-59.94%	-42.17%
Acquisitions
YoY Change
Other Investing Activities	-$372.0K	-$239.0K	-$5.035M
YoY Change	-90.1%
Cash From Investing Activities	-$7.250M	-$9.078M	-$58.81M
YoY Change	-69.22%	-58.86%	-36.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$360.2M
YoY Change			44.54%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$5.886M	100.4M	$4.466M
YoY Change	-101.66%	-47.56%	-98.63%
NET CHANGE
Cash From Operating Activities	-$83.60M	-176.8M	-$714.0M
Cash From Investing Activities	-$7.250M	-9.078M	-$58.81M
Cash From Financing Activities	$5.886M	100.4M	$4.466M
Net Change In Cash	-$87.87M	-85.47M	-$765.0M
YoY Change	-87.66%	-265.77%	326.41%
FREE CASH FLOW
Cash From Operating Activities	-$83.60M	-$176.8M	-$714.0M
Capital Expenditures	$6.878M	$8.839M	$53.77M
Free Cash Flow	-$90.48M	-$185.6M	-$767.8M
YoY Change	-73.8%	32.7%	50.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.41
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.42
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74400000	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-657939000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1743751000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-8368000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1743751000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-351673000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	19428000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	12606000	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.novavax.com/20231231#LeaseRightOfUseAsset
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.novavax.com/20231231#LeaseRightOfUseAsset
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.novavax.com/20231231#LeaseRightOfUseAsset
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.novavax.com/20231231#LeaseRightOfUseAsset
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-26770
CY2023	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX, INC
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-2816046
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	700 Quince Orchard Road,
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg,
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20878
CY2023	dei	City Area Code CityAreaCode	(240)
CY2023	dei	Local Phone Number LocalPhoneNumber	268-2000
CY2023	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01 per share
CY2023	dei	Trading Symbol TradingSymbol	NVAX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	699000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	139953143	shares
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Tysons, Virginia
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Tysons, Virginia
CY2023	us-gaap	Revenues Revenues	983705000	usd
CY2022	us-gaap	Revenues Revenues	1981872000	usd
CY2021	us-gaap	Revenues Revenues	1146290000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	343768000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	902639000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	737502000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1235278000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2534508000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	468946000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	488691000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	298358000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	1550216000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	2626608000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	2832866000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-566511000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-644736000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-1686576000	usd
CY2023	us-gaap	Interest Expense InterestExpense	14416000	usd
CY2022	us-gaap	Interest Expense InterestExpense	19880000	usd
CY2021	us-gaap	Interest Expense InterestExpense	21127000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	37896000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10969000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6833000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-543031000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-653647000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1714536000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2031000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4292000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29215000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-545062000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-657939000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1743751000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.42
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-23.44
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-23.44
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100768000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78183000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74400000	shares
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-9000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-535963000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	568505000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1336883000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10424000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10303000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	297240000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	82375000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	41696000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	36683000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	226023000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	237147000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1143888000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1703391000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	305771000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	294247000	usd
CY2023Q4	nvax	Lease Right Of Use Asset LeaseRightOfUseAsset	185218000	usd
CY2022Q4	nvax	Lease Right Of Use Asset LeaseRightOfUseAsset	106241000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	127454000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	126331000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35159000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	28469000	usd
CY2023Q4	us-gaap	Assets Assets	1797490000	usd
CY2022Q4	us-gaap	Assets Assets	2258679000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	132610000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	216517000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	394668000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	591158000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	241310000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	370137000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	5142000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27196000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	324881000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	861408000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	930055000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1635138000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2459944000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	622210000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	179414000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	168016000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	166466000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	55923000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	31238000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	33130000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	55695000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2514417000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2892757000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	140506093	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	139505770	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86806554	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86039923	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1405000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	868000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4192164000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3737979000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4820951000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4275889000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1000323	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	766631	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	92267000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	90659000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2722000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6377000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-716927000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-634078000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1797490000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2258679000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627209000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	183626000	usd
CY2021	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	24761000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	7292000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	564859000	usd
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-9000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	131967000	usd
CY2022	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	-639000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	7216000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	249230000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-5024000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-657939000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-634078000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	85850000	usd
CY2023	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	159000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	6171000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	367105000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	9099000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-545062000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-716927000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-545062000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-657939000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1743751000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	41225000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	29054000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12661000	usd
CY2023	nvax	Operating And Finance Lease Write Off OperatingAndFinanceLeaseWriteOff	6113000	usd
CY2022	nvax	Operating And Finance Lease Write Off OperatingAndFinanceLeaseWriteOff	18104000	usd
CY2021	nvax	Operating And Finance Lease Write Off OperatingAndFinanceLeaseWriteOff	144433000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	85357000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	130300000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	183626000	usd
CY2023	nvax	Provision For Excess And Obsolete Inventory ProvisionForExcessAndObsoleteInventory	72197000	usd
CY2022	nvax	Provision For Excess And Obsolete Inventory ProvisionForExcessAndObsoleteInventory	447597000	usd
CY2021	nvax	Provision For Excess And Obsolete Inventory ProvisionForExcessAndObsoleteInventory	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10081000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	7042000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	21903000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	7641000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	74457000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	477801000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8872000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	274442000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-249166000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	183393000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-378805000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	913399000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	600326000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	350868000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1045914000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1325557000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-713967000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-415937000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	322946000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10338000	usd
CY2023	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	53771000	usd
CY2022	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	89056000	usd
CY2021	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	54501000	usd
CY2023	us-gaap	Payments For Software PaymentsForSoftware	5035000	usd
CY2022	us-gaap	Payments For Software PaymentsForSoftware	3929000	usd
CY2021	us-gaap	Payments For Software PaymentsForSoftware	2985000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2167000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	159807000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-58806000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-92985000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	100154000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	360243000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	249230000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	564859000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	175250000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2023	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3591000	usd
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	5258000	usd
CY2021	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	usd
CY2023	nvax	Net Proceeds From The Exercise Of Stock Based Awards NetProceedsFromTheExerciseOfStockBasedAwards	159000	usd
CY2022	nvax	Net Proceeds From The Exercise Of Stock Based Awards NetProceedsFromTheExerciseOfStockBasedAwards	-639000	usd
CY2021	nvax	Net Proceeds From The Exercise Of Stock Based Awards NetProceedsFromTheExerciseOfStockBasedAwards	24761000	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	325000000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27345000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	93595000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	127907000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4466000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	324988000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	461713000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3272000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4520000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5292000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-765035000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-179414000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	879521000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1348845000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1528259000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	648738000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	583810000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1348845000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1528259000	usd
CY2023	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled	6862000	usd
CY2022	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled	0	usd
CY2021	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled	0	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7899000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	17665000	usd
CY2023	nvax	Non Cash Related Transactions For Finance Lease Right Of Use Asset NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset	103299000	usd
CY2022	nvax	Non Cash Related Transactions For Finance Lease Right Of Use Asset NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset	91855000	usd
CY2021	nvax	Non Cash Related Transactions For Finance Lease Right Of Use Asset NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset	179210000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	17349000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	18035000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	190000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	17980000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	Organization & Business<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax, Inc. (“Novavax,” and together with its wholly owned subsidiaries, the “Company”) is a biotechnology company that promotes improved health by discovering, developing, and commercializing innovative vaccines to prevent serious infectious diseases. Novavax offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and patented Matrix-M™ adjuvant to enhance the immune response. Novavax currently has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid™ prototype COVID-19 vaccine ("NVX-CoV2373,” or “prototype vaccine”) and Nuvaxovid™ updated COVID-19 vaccine (“NVX-CoV2601,” or “updated vaccine”) (collectively, “COVID-19 Vaccine”). Local regulatory authorities have also specified nomenclature for the prototype and updated vaccines within their territories (e.g., “Novavax COVID-19 Vaccine, Adjuvanted” and “Novavax COVID-19, Adjuvanted (2023-2024 Formula)”, respectively, for the U.S.). The Company’s partner, Serum Institute of India Pvt. Ltd. (“SIIPL”), markets NVX-CoV2373 as “Covovax™.” </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, the Company received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization (“EUA”) from multiple regulatory authorities globally for its prototype vaccine for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in select territories. In October 2023, the U.S. Food and Drug Administration (“U.S. FDA”) amended the EUA for its prototype vaccine to include its updated vaccine. The amended EUA authorizes use of the Company’s updated vaccine in individuals 12 years and older. In October 2023, the European Commission (“EC”) granted approval for the Company’s updated vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older. Currently, the Company significantly depends on its supply agreement with SIIPL and its subsidiary, Serum Life Sciences Limited (“SLS”), for co-formulation, filling and finishing (other than in Europe) and on its service agreement with PCI Pharma Services for finishing in Europe. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax is advancing development of other vaccine candidates, including its COVID19-Influenza Combination (“CIC”) vaccine candidate and additional vaccine candidates. The Company’s COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M™ adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.</span></div>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	568500000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-545100000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-714000000	usd
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Inception To Date Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent	0.85
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	4500000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10100000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.
CY2023	us-gaap	Advertising Expense AdvertisingExpense	91500000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	84000000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	8900000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments expose the Company to concentration of credit risk and consist primarily of cash and cash equivalents. The Company’s investment policy limits investments to certain types of instruments, including asset-backed securities, high-grade corporate debt securities, and money market funds; places restrictions on maturities and concentrations in certain industries; and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions that may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently depends significantly on one supplier for co-formulation, filling, and finishing of COVID-19 Vaccine. The loss of this supplier could prevent or delay the Company’s delivery of customer orders.</span></div>
CY2023	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	2700000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-6400000	usd
CY2023	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	7900000	usd
CY2022	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	-2500000	usd
CY2021	us-gaap	Translation Adjustment Functional To Reporting Currency Gain Loss Reclassified To Earnings Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax	-5300000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	286400000	usd
CY2022Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	53800000	usd
CY2023Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	10800000	usd
CY2022Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	28600000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	96210000	usd
CY2023	nvax	Accounts Receivable Before Allowance For Credit Loss Additions AccountsReceivableBeforeAllowanceForCreditLossAdditions	1472768000	usd
CY2023	nvax	Accounts Receivable Before Allowance For Credit Loss Deductions AccountsReceivableBeforeAllowanceForCreditLossDeductions	1264062000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	304916000	usd
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	454993000	usd
CY2022	nvax	Accounts Receivable Before Allowance For Credit Loss Additions AccountsReceivableBeforeAllowanceForCreditLossAdditions	1768457000	usd
CY2022	nvax	Accounts Receivable Before Allowance For Credit Loss Deductions AccountsReceivableBeforeAllowanceForCreditLossDeductions	2127240000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	96210000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	13835000	usd
CY2023	nvax	Accounts Receivable Allowance For Credit Loss Deductions AccountsReceivableAllowanceForCreditLossDeductions	-6159000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	7676000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	13835000	usd
CY2022	nvax	Accounts Receivable Allowance For Credit Loss Deductions AccountsReceivableAllowanceForCreditLossDeductions	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	13835000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	549551000	usd
CY2023	nvax	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	581569000	usd
CY2023	nvax	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	267599000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	863521000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1595472000	usd
CY2022	nvax	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	46908000	usd
CY2022	nvax	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	1092829000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	549551000	usd
CY2022	nvax	Accounts Receivable Allowance For Credit Loss Additions AccountsReceivableAllowanceForCreditLossAdditions	13800000	usd
CY2023	nvax	Accounts Receivable Allowance For Credit Loss Deductions AccountsReceivableAllowanceForCreditLossDeductions	-6200000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	241300000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	400000000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1400000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	622200000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	179400000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	172500000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2000000000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	13912000	usd
CY2020Q4	nvax	Purchase Agreement Number Of Vaccine Doses PurchaseAgreementNumberOfVaccineDoses	60000000	dose
CY2023	nvax	Royalty Period RoyaltyPeriod	P15Y
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	568505000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1336883000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1515116000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10424000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10303000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	11490000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4881000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1659000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1653000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	583810000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1348845000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1528259000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6614000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	7392000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	21410000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	27690000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1361000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	41696000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	36683000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	72400000	usd
CY2023	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	-73500000	usd
CY2023	nvax	Inventory Firm Purchase Commitment Recoveries InventoryFirmPurchaseCommitmentRecoveries	40200000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	447600000	usd
CY2022	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	155900000	usd
CY2021	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	0	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	368383000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2023	nvax	Inventory Reserve Charged To Costs Of Sales InventoryReserveChargedToCostsOfSales	72441000	usd
CY2022	nvax	Inventory Reserve Charged To Costs Of Sales InventoryReserveChargedToCostsOfSales	447597000	usd
CY2023	nvax	Inventory Reserve Other Additions InventoryReserveOtherAdditions	65049000	usd
CY2022	nvax	Inventory Reserve Other Additions InventoryReserveOtherAdditions	0	usd
CY2023	nvax	Inventory Reserve Deductions InventoryReserveDeductions	239814000	usd
CY2022	nvax	Inventory Reserve Deductions InventoryReserveDeductions	79214000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	266059000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	368383000	usd
CY2023	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2022	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2022Q4	us-gaap	Goodwill Goodwill	126331000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	131479000	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	1123000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-5148000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	127454000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	126331000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24985000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36384000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	160233000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	69857000	usd
CY2023Q4	nvax	Lease Right Of Use Asset LeaseRightOfUseAsset	185218000	usd
CY2022Q4	nvax	Lease Right Of Use Asset LeaseRightOfUseAsset	106241000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	22977000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	16867000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	5142000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27196000	usd
CY2023Q4	nvax	Lease Liability Current LeaseLiabilityCurrent	28119000	usd
CY2022Q4	nvax	Lease Liability Current LeaseLiabilityCurrent	44063000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28577000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50085000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	55923000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	31238000	usd
CY2023Q4	nvax	Lease Liability Noncurrent LeaseLiabilityNoncurrent	84500000	usd
CY2022Q4	nvax	Lease Liability Noncurrent LeaseLiabilityNoncurrent	81323000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P11Y7M6D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P8Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.064
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.089
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.054
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	6929000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	6903000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	37027000	usd
CY2023	nvax	Short Term Lease Cost Benefit ShortTermLeaseCostBenefit	-48009000	usd
CY2022	nvax	Short Term Lease Cost Benefit ShortTermLeaseCostBenefit	94726000	usd
CY2021	nvax	Short Term Lease Cost Benefit ShortTermLeaseCostBenefit	468210000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	10292000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	6836000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	116435000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	12876000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	7759000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	112528000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2605000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1472000	usd
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	7241000	usd
CY2023	us-gaap	Lease Cost LeaseCost	15481000	usd
CY2022	us-gaap	Lease Cost LeaseCost	9231000	usd
CY2021	us-gaap	Lease Cost LeaseCost	119769000	usd
CY2023	nvax	Short Term Lease Cost Benefit ShortTermLeaseCostBenefit	-48000000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	101297000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	190158000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	203991000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2605000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1472000	usd
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	7241000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27345000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	93595000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	127907000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	30675000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	66682000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	103299000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	73240000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	112528000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	34353000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	17192000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	13616000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	14000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	14375000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	67296000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	160832000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	48213000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	112619000	usd
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	0	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	119000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	324881000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	7234000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	8784000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	168016000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	166466000	usd
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	9779000	usd
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	12542000	usd
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	12188000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1689000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1497000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1424000	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	11468000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	14039000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	13612000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	85357000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	130300000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	183626000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	500000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1700000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	81400000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5000000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	21000000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	454000000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	100000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	100000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.04
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	7000000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	6000000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3400000	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	22853000	usd
CY2023Q4	us-gaap	Supplies Supplies	70297000	usd
CY2022Q4	us-gaap	Supplies Supplies	160773000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	155726000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	76374000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	226023000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	237147000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	380739000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	341539000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	74968000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47292000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	305771000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	294247000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	41000000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	29000000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13000000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	55952000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	52569000	usd
CY2023Q4	nvax	Accrued Gross To Net Deductions Current AccruedGrossToNetDeductionsCurrent	20616000	usd
CY2022Q4	nvax	Accrued Gross To Net Deductions Current AccruedGrossToNetDeductionsCurrent	0	usd
CY2023Q4	nvax	U.S.Product Sales Returns Accrual U.S.ProductSalesReturnsAccrual	82506000	usd
CY2022Q4	nvax	U.S.Product Sales Returns Accrual U.S.ProductSalesReturnsAccrual	0	usd
CY2023Q4	nvax	Research And Development Accruals Current ResearchAndDevelopmentAccrualsCurrent	131027000	usd
CY2022Q4	nvax	Research And Development Accruals Current ResearchAndDevelopmentAccrualsCurrent	468214000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	104567000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	70375000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	394668000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	591158000	usd
CY2023Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	142165000	usd
CY2022Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	210362000	usd
CY2023Q4	nvax	Other Current Liability Related To Advance Purchase Agreements OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements	696390000	usd
CY2022Q4	nvax	Other Current Liability Related To Advance Purchase Agreements OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements	697384000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	22309000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	861408000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	930055000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-628984000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-712183000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1633016000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	85953000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	58536000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-81520000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-543031000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-653647000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1714536000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-1300000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1300000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-157000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	503000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1445000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2489000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	29215000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-12000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4292000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	29215000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	2043000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2031000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4292000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29215000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.01
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.02
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.01
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.01
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.01
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.02
CY2023	nvax	Effective Income Tax Rate Reconciliation Tax Expense Benefit Non Cash Share Based Payment Arrangement Percent EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent	-0.01
CY2022	nvax	Effective Income Tax Rate Reconciliation Tax Expense Benefit Non Cash Share Based Payment Arrangement Percent EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent	-0.01
CY2021	nvax	Effective Income Tax Rate Reconciliation Tax Expense Benefit Non Cash Share Based Payment Arrangement Percent EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent	0.04
CY2023	nvax	Effective Income Tax Rate Reconciliation Us Taxation Of Foreign Operations EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations	-0.04
CY2022	nvax	Effective Income Tax Rate Reconciliation Us Taxation Of Foreign Operations EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations	-0.03
CY2021	nvax	Effective Income Tax Rate Reconciliation Us Taxation Of Foreign Operations EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations	0
CY2023	nvax	Effective Income Tax Rate Reconciliation Cancellation Of Indebtedness Percent EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent	-0.01
CY2022	nvax	Effective Income Tax Rate Reconciliation Cancellation Of Indebtedness Percent EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent	0
CY2021	nvax	Effective Income Tax Rate Reconciliation Cancellation Of Indebtedness Percent EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent	-0.01
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.04
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.02
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.20
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.20
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.02
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.30
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.01
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.02
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	550272000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	479134000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	5752000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	51878000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	45560000	usd
CY2023Q4	nvax	Deferred Tax Asset Leasing Liability DeferredTaxAssetLeasingLiability	25207000	usd
CY2022Q4	nvax	Deferred Tax Asset Leasing Liability DeferredTaxAssetLeasingLiability	27625000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	266392000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	195049000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	79386000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	213076000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	20756000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	30727000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	27599000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	132500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	49309000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	18679000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	10996000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13695000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1186793000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1056799000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1128941000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1020123000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	57852000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	36676000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	41456000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	23330000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	17160000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	11587000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1279000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1055000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	704000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	59895000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	36676000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2043000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	108800000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4800000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2000000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5194000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11154000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8766000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	271000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1260000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4158000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	807000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1228000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	8027000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1770000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4237000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	5194000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11154000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	4200000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	5200000	usd
CY2022Q4	us-gaap	Loss Contingency Number Of Defendants LossContingencyNumberOfDefendants	2	defendant
CY2022Q4	nvax	Loss Contingency Period To Answer LossContingencyPeriodToAnswer	P14D
CY2023Q4	us-gaap	Purchase Obligation PurchaseObligation	0	usd
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	4503000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10081000	usd
CY2023	us-gaap	Restructuring Charges RestructuringCharges	14584000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10100000	usd

Files In Submission

Name	View Source	Status
0001000694-24-000007-index-headers.html	Edgar Link	pending
0001000694-24-000007-index.html	Edgar Link	pending
0001000694-24-000007.txt	Edgar Link	pending
0001000694-24-000007-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image.jpg	Edgar Link	pending
image1a.jpg	Edgar Link	pending
image_01a.jpg	Edgar Link	pending
image_02a.jpg	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
image_0b.jpg	Edgar Link	pending
image_1a.jpg	Edgar Link	pending
image_2a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvax-20231231.htm	Edgar Link	pending
nvax-20231231.xsd	Edgar Link	pending
nvax-20231231xex10101.htm	Edgar Link	pending
nvax-20231231xex1028.htm	Edgar Link	pending
nvax-20231231xex1032.htm	Edgar Link	pending
nvax-20231231xex1033.htm	Edgar Link	pending
nvax-20231231xex1034.htm	Edgar Link	pending
nvax-20231231xex1035.htm	Edgar Link	pending
nvax-20231231xex1036.htm	Edgar Link	pending
nvax-20231231xex1037.htm	Edgar Link	pending
nvax-20231231xex21.htm	Edgar Link	pending
nvax-20231231xex231.htm	Edgar Link	pending
nvax-20231231xex311.htm	Edgar Link	pending
nvax-20231231xex312.htm	Edgar Link	pending
nvax-20231231xex321.htm	Edgar Link	pending
nvax-20231231xex322.htm	Edgar Link	pending
nvax-20231231xex44.htm	Edgar Link	pending
nvax-20231231xex97.htm	Edgar Link	pending
nvax-20231231_g1.jpg	Edgar Link	pending
nvax-20231231_g2.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
nvax-20231231_lab.xml	Edgar Link	unprocessable
nvax-20231231_pre.xml	Edgar Link	unprocessable
nvax-20231231_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nvax-20231231_def.xml	Edgar Link	unprocessable
nvax-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2024 Q1 Form 10-K Financial Statement

#000100069424000007 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2024 Q1 Form 10-K Financial Statement

#000100069424000007 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax